Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

NCT02432274 is registered in ClinicalTrials.gov with Eisai Limited as lead sponsor.

NCT NCT02432274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02432274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
Lead sponsor
Eisai Limited
Phase
Phase 1/2
Overall status
Completed
Start date
December 29, 2014
Completion date
July 20, 2022
Enrollment
117 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

differentiated thyroid cancer (dtc), osteosarcoma, solid malignant tumors, tumors